Meeting details menu

Meeting Authors
Meeting Abstracts
Keynote lectures
Oral communications
Poster presentations
Special symposia
Other

Acta Physiologica Congress

Back

Acta Physiologica 2006; Volume 186, Supplement 650
Joint Meeting of The German Society of Physiology and The Federation of European Physiological Societies 2006
3/26/2006-3/29/2006
Ludwig-Maximilians-University, Munich


CISPLATIN AND AS2O3 INCREASE INTRACELLULAR CALCIUM BY TWO DIFFERENT MECHANISMS IN MALIGNE CELLS
Abstract number: PW13P-10

Splettstoesser1 F, Florea1 AM, Busselberg1 D

1Universittsklinium Essen, Institut fr Physiologie

The interactions of metals with cell systems are not fully eluci-dated. Forms of metallic derivatives are highly toxic (mercury, led), and others are used in humans for diverse treatments in-cluding cancers (arsenic trioxide, cisplatin). We propose that modulation of calcium homeostasis induced by metallic deriva-tives could be an important mechanism in induced cytotoxicity. Using human cell models (neuroblastoma, osteosarcoma, cervix carcinoma, embryonic kidney cells) and confocal microscopy (Zeiss 510) with the calcium sensitive dye fluo 4-AM we found that cisplatin (cPt; 0.001 mM - 10 mM) and arsenic trioxide (As2O3; 0.0001 mM - 1 mM) trigger calcium signaling, the mechanism of calcium rise was drug, concentration and cell type specific. Steady state increase of [Ca2+]i and calcium-spikes were observed with both substances. While the rise was partly reversible with cPt, it was not reversible with As2O3. As2O3 released calcium from the internal stores and the calcium rise was initiated by the activation of inosithol-1,4,5-triphosphate or ryanodine receptors. The cPt induced calcium rise depends on the external calcium concentration, but was modified with the IP3receptor blocker 2-APB. The modulation of [Ca2+]i could be a key function to understand the beneficial as well as the toxic effects of cisplatin or As2O3.

To cite this abstract, please use the following information:
Acta Physiologica 2006; Volume 186, Supplement 650 :PW13P-10

Our site uses cookies to improve your experience.You can find out more about our use of cookies in our standard cookie policy, including instructions on how to reject and delete cookies if you wish to do so.

By continuing to browse this site you agree to us using cookies as described in our standard cookie policy .

CLOSE